Metastatic castration-sensitive prostate cancer – pfizer
Talazoparib is a potent, orally bioavailable, small molecule that is in development for the treatment of a variety of human cancers. In previous studies the combination of talazoparib and anti-PD-L1 antibody significantly reduced tumor growth and improved survival.
Revive Research Institute is conducting a research on Talazoparib to determine its efficacy in treatment of prostate cancer.
The investigational treatment is free for the duration of the clinical trial and insurance is not required.
- Be > 18 years of age.
- Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell or signet cell features
- Willing to provide tumor tissue when available (de novo or archived) for retrospective molecular profiling analysis.
- Additional Criteria may apply.